Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Bank of Ameri...
Quick Take Hookipa Pharma ( HOOK ) has filed proposed terms to raise $100 million in a U.S. IPO, per an amended registration statement . Hookipa is advancing a pipeline of immunotherapeutics for infectious diseases and cancers. HOOK has generated promising trial results for its lead can...
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the completion of enrollment in NT-002, its Phase 1b clinical trial evaluating NEO-PV-01 with KEYTR...
Gainers: Ocean Power Technologies (NASDAQ: OPTT ) +176% . Netshoes (Cayman) (NYSE: NETS ) +23% . Evogene (NASDAQ: EVGN ) +22% . Zynerba Pharmaceuticals (NASDAQ: ZYNE ) +21% . DMC Global (NASDAQ: BOOM ) +19% . Fuel Tech (NASDAQ: FTEK ) +18% . VivoPower International (NASDAQ: VVP...
Thinly traded micro cap Neon Therapeutics ( NTGN +9.9% ) is up on average volume following the release of updated data from a Phase 1b clinical trial, NT-001 , evaluating personalized neoantigen vaccine NEO-PV-01, combined with Bristol-Myers Squibb's ( BMY -0.3% ) Opdivo (nivolumab), ...
Post-Vaccine Immune and Pathologic Markers Associated with Durable Clinical Benefit in Metastatic Melanoma Patient Cohort Top-line Results, Including 52-Week Clinical Outcomes, from Full NT-001 Trial in Melanoma, Non-Small Cell Lung and Bladder Cancers Expected Later in 1H 2019 CAM...
Noteworthy events during the week of March 24 - 30 for healthcare investors. More news on: Cidara Therapeutics, Inc., Recro Pharma, Inc., Autolus Therapeutics plc, Healthcare stocks news, , Read more ...
Neon Therapeutics (NASDAQ: NTGN ): Q4 GAAP EPS of -$0.84. Cash, cash equivalents and marketable securities $103.3M Press Release More news on: Neon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results for the fourth quarter and full-year ended December 31, 2018 and pr...
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Cowen and C...
News, Short Squeeze, Breakout and More Instantly...
Neon Therapeutics Inc. Company Name:
NTGN Stock Symbol:
NASDAQ Market:
Neon Therapeutics Inc. Website:
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced the acceptance of its Clinical Trial Authorization (CTA) from the Dutch Health Authority (DHA) for its personal neoantigen-targeted T cell therapy candidate, NEO-PTC-01. Neon...
BNT111 FixVac Melanoma registrational trial start planned for 2H 2020 BNT121 (iNeST) adjuvant Phase 2 study in NSCLC to start in 2H 2020 COVID-19 vaccine program BNT162 set to enter the clinic in April 2020 Ended 2019 with cash equivalents of $583 million ( €520 millio...
NEW YORK, NY / ACCESSWIRE / February 13, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Forescout Technologies, Inc. (NASDAQ: FSCT )...